On April 17, 2023 BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, reported that it will present a poster, titled "Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential," at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 on April 18 in Orlando (Press release, Bridgene Biosciences, APR 17, 2023, View Source [SID1234630204]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pharmacological inhibitors of TEAD transcription factors have emerged as a promising novel class of anti-cancer agents. TEAD inhibitors disrupt oncogenic YAP/TAZ signaling, resulting in cell cycle arrest and cell death in susceptible cancers.

"Using our IMTAC live-cell chemoproteomic platform to identify small molecules against challenging targets, we have successfully identified several potent and drug-like covalent ligands for TEAD. Based on this discovery, we rapidly developed the pre-clinical candidate BGI-9004," said Wolf Wiedemeyer, Ph.D., BridGene’s head of biology. "The covalent TEAD inhibitor BGI-9004 has demonstrated promising activity both as a single agent and in combination with other targeted agents, a favorable pharmacokinetic profile and high target selectivity in preclinical models, supporting its evaluation as a novel anti-cancer agent in clinical trials."

Details regarding the poster presentation are as follows:

Event:

AACR Annual Meeting 2023

Title:

Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential

Abstract Number:

4976

Date:

Tuesday, April 18, 2023

Time:

1:30-5 p.m. ET

Location:

Poster Section 16, Poster 22

Orange County Convention Center, Orlando, Fla.